Literature DB >> 20810253

Crimean-Congo haemorrhagic fever in Eurasia.

Hakan Leblebicioglu1.   

Abstract

Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne infectious disease characterized by fever, malaise, headache, nausea, vomiting, diarrhoea, sore throat, muscle aches, haemorrhage and thrombocytopenia. It is a challenge for the population of endemic rural areas, and for healthcare workers, and carries a considerable mortality. The disease is widely distributed in Africa, Europe and Asia, and has become a serious threat to public health in Eurasia. The intention of this review is to summarize the current status of CCHF in Eurasia.
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20810253     DOI: 10.1016/j.ijantimicag.2010.06.020

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  28 in total

1.  Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease.

Authors:  Reed F Johnson; Lori E Dodd; Srikanth Yellayi; Wenjuan Gu; Jennifer A Cann; Catherine Jett; John G Bernbaum; Dan R Ragland; Marisa St Claire; Russell Byrum; Jason Paragas; Joseph E Blaney; Peter B Jahrling
Journal:  Virology       Date:  2011-10-19       Impact factor: 3.616

2.  Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever.

Authors:  Zulal Ozkurt; Kemalettin Ozden; Ilhami Kiki; Mustafa Usanmaz
Journal:  Eurasian J Med       Date:  2011-08

3.  Prevalence of Crimean-Congo hemorrhagic fever virus antibodies in Greek residents in the area where the AP92 strain was isolated.

Authors:  P Sidira; P Nikza; K Danis; T Panagiotopoulos; D Samara; Hc Maltezou; A Papa
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

4.  Seroepidemiological survey of Crimean-Congo hemorrhagic fever among sheep in Mazandaran province, northern Iran.

Authors:  Ehsan Mostafavi; Sadegh Chinikar; Saber Esmaeili; Fahimeh Bagheri Amiri; Amir Mohammad Ali Tabrizi; Sahar KhakiFirouz
Journal:  Vector Borne Zoonotic Dis       Date:  2012-08-23       Impact factor: 2.133

Review 5.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

6.  Direct healthcare costs for patients hospitalized with Crimean-Congo haemorrhagic fever can be predicted by a clinical illness severity scoring system.

Authors:  Ilkay Bozkurt; Mustafa Sunbul; Hava Yilmaz; Saban Esen; Hakan Leblebicioglu; Nicholas J Beeching
Journal:  Pathog Glob Health       Date:  2016-02-25       Impact factor: 2.894

7.  Association Between Severity Grading Score And Acute Phase Reactants In Patients With Crimean Congo Hemorrhagic Fever.

Authors:  Ilkay Bozkurt; Saban Esen
Journal:  Pathog Glob Health       Date:  2021-01-23       Impact factor: 2.894

8.  Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus.

Authors:  Nurettin Canakoglu; Engin Berber; Mustafa Ertek; Mustafa D Yoruk; Sukru Tonbak; Yusuf Bolat; Munir Aktas; Ahmet Kalkan; Aykut Ozdarendeli
Journal:  Virol J       Date:  2013-01-03       Impact factor: 4.099

9.  Diagnostic assays for Crimean-Congo hemorrhagic fever.

Authors:  Jessica Vanhomwegen; Maria João Alves; Tatjana Avšič Zupanc; Silvia Bino; Sadegh Chinikar; Helen Karlberg; Gülay Korukluoğlu; Miša Korva; Masoud Mardani; Ali Mirazimi; Mehrdad Mousavi; Anna Papa; Ana Saksida; Batool Sharifi-Mood; Persofoni Sidira; Katerina Tsergouli; Roman Wölfel; Hervé Zeller; Philippe Dubois
Journal:  Emerg Infect Dis       Date:  2012-12       Impact factor: 6.883

10.  Migratory birds, ticks, and crimean-congo hemorrhagic fever virus.

Authors:  Mats Lindeborg; Christos Barboutis; Christian Ehrenborg; Thord Fransson; Thomas G T Jaenson; Per-Eric Lindgren; Ake Lundkvist; Fredrik Nyström; Erik Salaneck; Jonas Waldenström; Björn Olsen
Journal:  Emerg Infect Dis       Date:  2012-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.